Dr. Stephan Rietiker, a dual citizen of both Switzerland and the United States, received his medical doctorate from the University of Zurich in 1982 and also qualified to practice medicine in the United States. He spent five years practicing internal medicine before moving into the Healthcare industry. Dr. Rietiker began his career with Roche in 1987 and thereafter held several senior positions in marketing / general management with Boehringer Mannheim and Schering Plough. Subsequently, he became Vice President and General Manager Europe for Covance Central Laboratory Services. In 2001, he was appointed President and CEO of Sulzer Medica (later Centerpulse) and was instrumental in resolving a landmark legal settlement in a major U.S. litigation. He was also responsible for restructuring the company which ultimately led to its acquisition by Zimmer in 2003. After a year as CEO and Director at Pendragon Medical AG, he took on the role of Executive Director and CEO at IMI Intelligent Medical Implants in 2004. In 2006, Dr. Rietiker left IMI and incorporated AurigaVision AG, a Switzerland based investment platform that focuses on promising developmental-stage healthcare companies. This activity led to his involvement with LifeWatch AG where he initially served as Executive Board Member and Interim CEO. After four months, he permanently was appointed CEO of LifeWatch AG, a position he still holds today. Dr. Rietiker also served as a Senior Advisor to Brown Brothers Harriman’s Corporate Finance team from 2006 – 2014. And, since 2014, Dr. Rietiker has been serving on the Board of Directors for California-based LoneStar Heart, a company developing breakthrough therapies against advanced heart failure.
Andrew Moore, a Swiss and British national, holds a Bachelor’s Degree in Statistics and Operational Research from the University of Leeds and is a qualified English Chartered Accountant (FCA), qualified English Tax Advisor (CTA) and a certified European Financial Analyst (CEFA). He started his career with Price Waterhouse before spending more than 20 years in banking, fifteen of which were with Credit Suisse in both London and Zurich. At Credit Suisse he initially acted as the CFO of a subsidiary in London before going on to hold senior positions in both investment and private banking in Zurich. In 2000 Mr. Moore moved into the private equity / venture capital field and focused on the healthcare sector. Following nearly 4 years as the Chief Investment Officer for two stock exchange quoted investment companies, Mr. Moore then held CFO / CEO positions in 3 different early stage companies, one of which was listed on AIM in London. Following the sale of the business of the AIM listed company and several project-based mandates Mr. Moore joined LifeWatch as Chief of Staff in March 2014 and was appointed CFO as of April 1, 2016.
Stephanie J. Kravetz, a citizen of the United States, received her Doctorate of Jurisprudence from William Mitchell College of Law in St. Paul, Minnesota, United States and her Bachelor’s Degree in Psychology and Chemical and Biological Sciences from the University of Minnesota, United States. She spent more than 15 years as a national litigator with the Law Firm of Robins, Kaplan Miller and Ciresi L.L.P. practicing in the areas of medical device, pharmaceutical, healthcare and biotechnology. Her clients consisted of Fortune 500 companies, including Medtronic, Inc. as well as individual clients. After leaving private practice, Ms. Kravetz joined the LifeWatch Group of Companies in 2011. She served in multiple roles including, Of Counsel and General Counsel for LifeWatch Services, Inc. before accepting her current position in March 2014 as Chief Legal Officer and Secretary for LifeWatch AG with responsibilities for the worldwide legal affairs of the Company. She also holds certifications in Healthcare Compliance and Corporate Business Compliance and directs the Global Governance, Risk and Compliance Strategies for the LifeWatch Group of Companies.
Dr. Christoph Heinzen, a citizen of Switzerland, received his PhD in bioprocess engineering from the Technical University ETH of Zurich in 1996 and his postgraduate degree in economics from ETH in Zurich in 1997. He began his career with The Boston Consulting Group in 1997 and managed several projects within the pharmaceutical and healthcare sectors. Subsequently, he became General Manager and CEO of Inotech AG, a start-up biotech company in Basel. He set-up a GMP bio-manufacturing facility and provided, as a contract manufacturer, clinical trial material for biotech and pharmaceutical companies. In 2009, he was appointed Head of Project Management at Spirig AG, a Swiss based dermatological company, where he was responsible for defining a new corporate strategy. After the acquisition of Spirig by Galderma SA (a subsidiary of Nestlé Skin Health) in 2013, he was appointed Head of Development of OTC products and was responsible for well-established Galderma brands such as Cetaphil®, Excipial® and Daylong®. In May 2015, he was appointed Head of the Project Management Office at LifeWatch AG in Zug and was promoted to Executive Vice President of Operations and Technology, responsible for R&D, IT and Operations in October 2015. In September 2016, the Board of LifeWatch AG promoted Dr. Heinzen to the Executive Management Team as Chief Operations and Technology Officer.